Sagent Pharmaceuticals, Inc. (SGNT) Tops Q2 EPS by 7c; Cuts FY12 Sales Outlook
Tweet Send to a FriendGet Alerts SGNT Hot Sheet
Trade SGNT Now!
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $42.7 million versus the consensus estimate of $40.4 million.
The Company anticipates reported net loss for fiscal 2012 to be in the range of $20 to $30 million. Sees FY2012 revenue of $180-$200 million, versus the consensus of $221.08 million. Prior outlook called for sales of $220 - $250 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Company anticipates reported net loss for fiscal 2012 to be in the range of $20 to $30 million. Sees FY2012 revenue of $180-$200 million, versus the consensus of $221.08 million. Prior outlook called for sales of $220 - $250 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jabil Circuit (JBL) Tops Q3 EPS by 2c; Issues Light Q4 Outlook; Will Realign Global Ops
- Mediabistro (MBIS) halted on circuit breaker; last up 82%
- John Wiley (JW-A) Misses Q4 EPS by 9c; Names New CFO; Updates on Restructuring
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Trading HaltsRelated Entities
EarningsComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Earnings
Leon David Peris MD. on Aug 12, 2012 08:45 AMMark as Spam | Reply to this comment
We are confidenat of of a rise in
Revenue and earnings.